Vera Therapeutics, Inc. (NASDAQ:VERA – Get Rating) – Wedbush issued their Q1 2022 EPS estimates for Vera Therapeutics in a report issued on Monday, April 18th. Wedbush analyst L. Chico anticipates that the company will post earnings per share of ($0.67) for the quarter. Wedbush has a “Outperform” rating and a $32.00 price objective on […]
Equities research analysts at Wedbush began coverage on shares of Vera Therapeutics (NASDAQ:VERA – Get Rating) in a report issued on Monday, The Fly reports. The brokerage set an “outperform” rating on the stock. VERA has been the topic of several other reports. Zacks Investment Research lowered Vera Therapeutics from a “hold” rating to a […]
Vera Therapeutics, Inc. (NASDAQ:VERA – Get Rating) Director Patrick G. Enright acquired 333,333 shares of the business’s stock in a transaction dated Thursday, February 10th. The shares were purchased at an average price of $15.00 per share, with a total value of $4,999,995.00. The acquisition was disclosed in a legal filing with the SEC, which […]